Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.
 |
Vidyya |
|
Ars Medica Home |
|
Vidyya Archives |
|
Search Vidyya |
|
Ex Libris |
|
Subscriptions |
|
About Vidyya |
|
|
|
In Today's Vidyya The US FDA has approved an injectable medication for the treatment of osteoarthritis. |
|
FDA Approves New Treatment For Invasive Fungal Infection The FDA has approved Cancidas (caspofungin acetate) Intravenous Infusion, a new anti-fungal medication for patients who are unresponsive to or cannot tolerate standard therapies for the invasive form of aspergillosis. Cancidas is the first approved drug in a new class of anti-fungal agents called echinocandins, which are believed to work by disrupting the creation of fungal cell walls. More... |
|
Drug Decreases Blood Vessel Stiffness In Older Primates A novel drug that breaks down vascular collagen bonds in the body significantly decreased the stiffness of blood vessels in older non-human primates, according to a study conducted by National Institute on Aging (NIA) scientists and others. The finding suggests the medication could be a new treatment for high blood pressure, heart failure, and certain vascular complications of diabetes. More... |
|
NIH Course On Human Research Protections Goes Online
Vidyya keeps an eye on resources that will help our readers in their everyday lives. In that vein, we have discovered that the National Cancer Institute has developed a Web-based tool to help researchers, physicians, and nurses protect research participants. More... |
|
Study Underway To Test Anti-Inflammatory Medicines For Prevention Of Alzheimer's Disease Alzheimer's disease affects up to 4 million Americans. If no cure is found, that number could double in 20 years as baby boomers age. On 30 January, the Alzheimer's Disease Anti-inflammatory Prevention Trial, or ADAPT, will begin to test whether anti-inflammatory pain relievers could prevent this degenerative brain disease. More... |
|
New Osteoarthritis Drug Receives FDA Approval Smith & Nephew Orthopaedics has received Food & Drug Administration approval for Supartz, a joint fluid therapy to treat osteoarthritis. In the United States, an estimated 20 million individuals suffer from osteoarthritis (OA) so the approval of another treatment will be welcome and successful. More... |
Ars Medica Home | Ex Libris | Vidyya |
Subscription Information | About Vidyya | Vidyya Archives |
Editor: Susan K. Boyer, RN
© RAmEx Ars Medica, Inc. All rights reserved.